ClinicalTrials.gg
Active, not recruitingNCT05710198Updated Nov 16, 2026

Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma

A Phase 3 interventional study of Citicoline eye drops 2% and Placebo in Glaucoma, Open-Angle, sponsored by Omikron Italia S.r.l.. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Omikron Italia S.r.l. · Phase 3, Interventional, and Prevention

How we know

Updated Nov 16, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
873
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Glaucoma, Open-Angle with a site in Italy — 1 open to participants now, 3 under way, 1 of them phase 3. Glaucoma, Open-Angle · Italy.

Enrollment
3rd of 25
873 · median 112
Started
2023
the only one that year
Phase 3
6 of 35
none open now
Registered
32nd of 35
by date

Among the 35 studies in Glaucoma, Open-Angle with a site in Italy, this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2023, is one of 6 in phase 3, and was the 32nd registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 35 studies in Glaucoma, Open-Angle with a site in Italy is open now. Recruiting first, the newest first:

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Glaucoma, Open-Angle with a site in Italy, or all of them as a file.
02

Study summary

To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice. Secondary objectives are assessing the effect of citicoline eye drops 2% on changes in structural parameters measured by Spectral Domain Optical Coherence Tomography (SD-OCT) and evaluating the safety of citicoline eye drops 2%

Read the detailed description

Background: Primary open angle glaucoma (OAG) is a chronic progressive neurodegenerative disease where intraocular pressure (IOP) is the main and successfully treatable risk factor. Although the treatment effect is quite large, a significant proportion of patients show disease progression with apparently well controlled IOP. Given the similarities with other neurodegenerative diseases - particularly in the mechanisms of cell death - neuroprotective treatments have been tested also in glaucoma. Interesting results from experimental studies and first evidence from human glaucoma trials have been published in recent years.

Citicoline is one of the promising molecules with a putative neuroprotective action and has been evaluated in patients with various neurodegenerative diseases with encouraging results. The mechanism of action of citicoline is multifarious and includes preservation of cardiolipin and sphingomyelin, restoration of phosphatidylcholine, stimulation of glutathione synthesis, lowering of glutamate concentration, rescuing mitochondrial function, and others. Pilot studies on glaucomatous patients showed a possible effect of citicoline as additive therapy in the treatment of glaucoma, in reducing progression of visual field changes, in protecting retinal nerve fiber layers and in improving vision related Quality of Life (QoL), though these findings are yet to be confirmed by a large randomized clinical trial.

03

Conditions studied

  • Glaucoma, Open-Angle

Keywords

  • Glaucoma
  • Citicoline
  • Visual field
  • Open-Angle glaucoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written .
  2. Age ≥ 18 years.
  3. Eyes with OAG, Pseudoexfoliation and pigmentary glaucoma will be included.
  4. Best Corrected Visual Acuity (BCVA) ≥ 0.5 for the study eye.
  5. Controlled IOP (≤ 18 mmHg, average of the last 3 measurements in the clinic) in the study eye.
  6. Visual field MD not worse than -12 dB at the latest assessment in the clinic for the study eye.
  7. Deteriorating MD at a rate between -0.5 dB/year and -1.0 dB/year, estimated from the latest VF tests collected in the clinic (at least 4) over a period during which incisional glaucoma surgery was not performed. Combinations of SITA Standard and Fast strategies (but not SITA Faster) is admissible. Patients who reach the desired minimum number of tests (4) with a mixture of SITA Standard/Fast and SITA Faster tests will need to perform additional replacement tests according to the prevalent strategy used in their series of VF (i.e. additional SITA Standard/Fast tests if ≤ 2 tests were SITA Faster; additional SITA Faster if > 2 tests were SITA Faster).
  8. Glaucoma definition will be based on VF damage (24-2, any SITA strategy) and spatially congruent glaucomatous changes at the ONH. If both eyes are eligible, the eye with the better MD will be chosen as the study eye.
  9. Women of willing to use an appropriate method of .

Exclusion criteria

Exclusion Criteria:

  1. Cataract in the study eye which, in the opinion of the clinician, may require cataract surgery within the next three years.
  2. Only-eye patients (visual acuity \< 0.1 decimals in one eye or more than two paracentral VF locations with a sensitivity of \< 10 dB).
  3. Known intolerance or allergy to any of the components in the eye drops.
  4. Diode laser treatment or glaucoma surgery in the past 2 years or cataract surgery within the last 6 months in the study eye.
  5. Eyes with any type of glaucoma other than primary, pseudoexfoliative or pigmentary OAG.
  6. Patients with other ocular or systemic comorbidities that, in the opinion of the Investigator, might affect the VF or the execution of the test.
  7. Patients already on topical or systemic citicoline treatment.
  8. Patients taking other systemic or topical potential neuroprotectors competing with citicoline eye drops 2% (a list will be provided) unwilling to suspend these treatments and undergo a of 6 months prior to the study.
  9. Patients unable to perform reliable VF tests, based on the assessment of the last 4 available 24-2 Humphrey Field Analyzer (HFA) VF tests performed in the clinic with a false positive rate (FP) ≤ 15%.
  10. Pregnant and nursing patients.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
873 participants (actual)

Study arms

  • Experimental
    citicoline eye drops 2%

    Citicoline eye drops 2%. One drop in the study eye three times daily throughout the 3-year trial. Patients will be treated with any IOP-lowering agent to control IOP and study treatments should be administered at least 20 minutes after IOP lowering medication.

    Drug: Citicoline eye drops 2%

  • Placebo comparator
    Placebo eye drops

    Placebo eye drops. One drop in the study eye three times daily throughout the 3-year trial. Patients will be treated with any IOP-lowering agent to control IOP and study treatments should be administered at least 20 minutes after IOP lowering medication

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Progression of visual field damage

    Difference in the rate of progression of VF damage in the study eye between the two trial arms. This will be measured with repeated, planned visual field (VF) tests, all performed with a Humphrey Field Analyser (HFA, Zeiss Meditec, Dublin, CA) with the SITA Standard 24-2 strategy, over the span of three years.

    Time frame: 3 years

Secondary outcomes

  1. Rate of progression in structural parameters

    Difference in the rate of progression in structural parameters. These parameters focus on the ocular structures mostly damaged by glaucoma. The parameters of interest will be: * RNFL thickness measured with Optical Coherence Tomography (OCT). * Inner retina thickness in the macula (RNFL, Ganglion Cell Layer and Ganglion Cell + Inner Plexiform Layer complex).

    Time frame: 3 years

  2. Safety (IOP)

    Safety will be assured by regular assessments of adverse events and IOP. IOP will be carefully monitored and managed as per standard clinical practice (detailed management of IOP is reported later). Side effects from the neuroprotective drops or any IOP lowering treatment, including allergic reactions, ocular surface toxicity and signs of extraocular or intraocular inflammation, will be carefully assessed by the examiners and reported in the case report form (CRF). Any significant discomfort or adverse reactions to the drops or clear signs of inflammation will be reasons for early withdrawal

    Time frame: 3 years

  3. Visual Field recovery

    Evidence of neuro-recovery. The Visual field Mean Deviation values (2 tests) at Visit 2 will be compared between the two groups, after adjusting for the MD values at Visit 1 (baseline, 2 tests).

    Time frame: 3 years

07

Study locations

1 site
  • Presidio Ospedale San Paolo
    Milan, MI 20142, Italy
08

References and documents

Publications

  • Cavaterra D, Giammaria S, Pandino I, Zingale GA, Delli Paoli V, Fiore R, Michelessi M, Roberti G, Carnevale C, Tanga L, Cazzato D, Peroni E, Grasso G, Manni G, Bocedi A, Oddone F, Coletta M, Sbardella D, Tundo GR. Citicoline Triggers Proteome Remodeling and Proteostatic Adaptation: Evidence from Shotgun Proteomics. Pharmaceutics. 2026 Jan 1;18(1):61. doi: 10.3390/pharmaceutics18010061. PubMed 41599168 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jul 2029, 66 months after the start.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 66 months is above that.

Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Apr 2026 → Jul 2029 and completion Apr 2027 → Jul 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2023
First posted
Feb 2, 2023
StartActual
Dec 11, 2023
Primary completionEst.
Jul 1, 2029was Apr 2026
CompletionEst.
Jul 1, 2029was Apr 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 16, 2026
Sites
1 site added, 1 site removed
Show site
  • Presidio Ospedale San Paolo · Milan, Italy
Show 1 removed
  • Presidio Ospedale San Paolo · Milano, Italy
Nov 16, 2026
Primary completion
Apr 1, 2026→Jul 1, 2029
Nov 16, 2026
Study completion
Apr 1, 2027→Jul 1, 2029
Nov 16, 2026
Enrollment
1000 (estimated)→873 (actual)
Nov 16, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41599168 ↗
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41599168 ↗
    1 site added, 1 site removed
    Show site
    • Presidio Ospedale San Paolo · Milan, Italy
    Show 1 removed
    • Presidio Ospedale San Paolo · Milano, Italy
    Primary completion Apr 1, 2026→Jul 1, 2029
    Study completion Apr 1, 2027→Jul 1, 2029
    Enrollment 1000 (estimated)→873 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05710198
Lead sponsor
Omikron Italia S.r.l.
Collaborators
OPIS Spain
Responsible party
Sponsor
First posted
Feb 2, 2023
Start date
Dec 11, 2023
Primary completion
Jul 1, 2029 (estimated)
Completion
Jul 1, 2029 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytidine Diphosphate Choline

Start the discussion